Research Paper Volume 12, Issue 24 pp 25700—25717

Figure 4. Epistatic analysis of par-1 for its effects on lifespan. (A) Survival curves of the daf-16 mutant treated with the control or par-1 RNAi (p < 0.0001, log-rank test). (B) Survival curves of the daf-2 mutant treated with the control or par-1 RNAi (p < 0.0001, log-rank test). (C) Survival curves of the glp-1 mutant treated with the control or par-1 RNAi (p < 0.0001, log-rank test). (D) Survival curves of the eat-2 mutant treated with the control or par-1 RNAi (p = 0.1489, log-rank test). (E) Survival curves of the rsks-1 mutant treated with the control or par-1 RNAi (p = 0.7661, log-rank test). (F) Survival curves of the aak-2 mutant treated with the control or par-1 RNAi (p = 0.4647, log-rank test). In all cases, animals were treated with the control or par-1 RNAi during the adulthood. Detailed quantitative data and statistical analyses are included in Supplementary Table 1.